Emergent treatments based on the pathophysiology of bipolar disorder: A selective review

Asian Journal of Psychiatry

Volumn 18, Issue , 2015, Pages 15-21

  Brady, Roscoe O ^a,b   Keshavan, Matcheri ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bipolar disorder; Depression; Genetics; Mania; TMS

Indexed keywords

ACETYLCYSTEINE; ISRADIPINE; KETAMINE; LITHIUM SALT; MEDROXYPROGESTERONE ACETATE; NEUROLEPTIC AGENT; PLACEBO; RILUZOLE; TAMOXIFEN; THIOCTIC ACID; VALPROIC ACID; CACNA1C PROTEIN, HUMAN; CALCIUM CHANNEL L TYPE; PSYCHOTROPIC AGENT;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; HUMAN; MANIA; MOLECULAR BIOLOGY; NEUROANATOMY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; BEHAVIOR; DIAGNOSIS; GENETICS; METABOLISM; PHARMACOGENETICS; PROCEDURES; PSYCHOLOGY; PSYCHOSOMATICS;

BEHAVIORAL SYMPTOMS; BIPOLAR DISORDER; CALCIUM CHANNELS, L-TYPE; HUMANS; PHARMACOGENETICS; PSYCHOSOMATIC MEDICINE; PSYCHOTROPIC DRUGS;

EID: 84955361477     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2015.07.017     Document Type: Review

References (57)

1. Amrollahi Z., Rezaei F., Salehi B., Modabbernia A.H., Maroufi A., Esfandiari G.R., Naderi M., Ghebleh F., Ahmadi-Abhari S.A., Sadeghi M., Tabrizi M., Akhondzadeh S. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J. Affect. Disord. 2011, 129:327-331.
2. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch. Gen. Psychiatry 2010, 67:360-368.
3. Angst J., Gamma A., Sellaro R., Lavori P.W., Zhang H. Recurrence of bipolar disorders and major depression. A life-long perspective. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:236-240.
4. Bebchuk J.M., Arfken C.L., Dolan-Manji S., Murphy J., Hasanat K., Manji H.K. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 2000, 57:95-97.
5. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Bush A.I. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol. Psychiatry 2008, 64:468-475.
6. Berk M., Dean O., Cotton S.M., Gama C.S., Kapczinski F., Fernandes B.S., Kohlmann K., Jeavons S., Hewitt K., Allwang C., Cobb H., Bush A.I., Schapkaitz I., Dodd S., Malhi G.S. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J. Affect. Disord. 2011, 135:389-394.
7. Berk M., Dean O.M., Cotton S.M., Gama C.S., Kapczinski F., Fernandes B., Kohlmann K., Jeavons S., Hewitt K., Moss K., Allwang C., Schapkaitz I., Cobb H., Bush A.I., Dodd S., Malhi G.S. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med. 2012, 10:91.
8. Brennan B.P., Hudson J.I., Jensen J.E., McCarthy J., Roberts J.L., Prescot A.P., Cohen B.M., Pope H.G., Renshaw P.F., Ongur D. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010, 35:834-846.
9. Brennan B.P., Jensen J.E., Hudson J.I., Coit C.E., Beaulieu A., Pope H.G., Renshaw P.F., Cohen B.M. A placebo-controlled trial of acetyl-l-carnitine and alpha-lipoic acid in the treatment of bipolar depression. J. Clin. Psychopharmacol. 2013, 33:627-635.
10. Casamassima F., Hay A.C., Benedetti A., Lattanzi L., Cassano G.B., Perlis R.H. L-type calcium channels and psychiatric disorders: a brief review. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2010, 153B:1373-1390.
11. Chen C.H., Lee C.S., Lee M.T., Ouyang W.C., Chen C.C., Chong M.Y., Wu J.Y., Tan H.K., Lee Y.C., Chuo L.J., Chiu N.Y., Tsang H.Y., Chang T.J., Lung F.W., Chiu C.H., Chang C.H., Chen Y.S., Hou Y.M., Chen C.C., Lai T.J., Tung C.L., Chen C.Y., Lane H.Y., Su T.P., Feng J., Lin J.J., Chang C.J., Teng P.R., Liu C.Y., Chen C.K., Liu I.C., Chen J.J., Lu T., Fan C.C., Wu C.K., Li C.F., Wang K.H., Wu L.S., Peng H.L., Chang C.P., Lu L.S., Chen Y.T., Cheng A.T., Taiwan Bipolar C. Variant GADL1 and response to lithium therapy in bipolar I disorder. N. Engl. J. Med. 2014, 370:119-128.
12. Clay H.B., Sillivan S., Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int.l J. Dev. Neurosci. 2011, 29:311-324.
13. Consortium on Lithium G., Hou L., Heilbronner U., Rietschel M., Kato T., Kuo P.H., McMahon F.J., Schulze T.G. Variant GADL1 and response to lithium in bipolar I disorder. N. Engl. J. Med. 2014, 370:1857-1859.
14. Craddock N., Sklar P. Genetics of bipolar disorder. Lancet 2013, 381:1654-1662.
15. Crump C., Sundquist K., Winkleby M.A., Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013, 70:931-939.
16. Dell'osso B., D'Urso N., Castellano F., Ciabatti M., Altamura A.C. Long-term efficacy after acute augmentative repetitive transcranial magnetic stimulation in bipolar depression: a 1-year follow-up study. J. ECT 2011, 27:141-144.
17. Dell'Osso B., Mundo E., D'Urso N., Pozzoli S., Buoli M., Ciabatti M., Rosanova M., Massimini M., Bellina V., Mariotti M., Altamura A.C. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord. 2009, 11:76-81.
18. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.A. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67:793-802.
19. Dolberg O.T., Dannon P.N., Schreiber S., Grunhaus L. Transcranial magnetic stimulation in patients with bipolar depression: a double blind, controlled study. Bipolar Disord. 2002, 4(Suppl. 1):94-95.
20. Ferreira M.A., O'Donovan M.C., Meng Y.A., Jones I.R., Ruderfer D.M., Jones L., Fan J., Kirov G., Perlis R.H., Green E.K., Smoller J.W., Grozeva D., Stone J., Nikolov I., Chambert K., Hamshere M.L., Nimgaonkar V.L., Moskvina V., Thase M.E., Caesar S., Sachs G.S., Franklin J., Gordon-Smith K., Ardlie K.G., Gabriel S.B., Fraser C., Blumenstiel B., Defelice M., Breen G., Gill M., Morris D.W., Elkin A., Muir W.J., McGhee K.A., Williamson R., MacIntyre D.J., MacLean A.W., St C.D., Robinson M., Van Beck M., Pereira A.C., Kandaswamy R., McQuillin A., Collier D.A., Bass N.J., Young A.H., Lawrence J., Ferrier I.N., Anjorin A., Farmer A., Curtis D., Scolnick E.M., McGuffin P., Daly M.J., Corvin A.P., Holmans P.A., Blackwood D.H., Gurling H.M., Owen M.J., Purcell S.M., Sklar P., Craddock N. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 2008, 40:1056-1058.
21. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet 2013, 381:1672-1682.
22. Geoffroy P.A., Bellivier F., Leboyer M., Etain B. Can the response to mood stabilizers be predicted in bipolar disorder?. Front. Biosci. 2014, 6:120-138.
23. Green E.K., Grozeva D., Jones I., Jones L., Kirov G., Caesar S., Gordon-Smith K., Fraser C., Forty L., Russell E., Hamshere M.L., Moskvina V., Nikolov I., Farmer A., McGuffin P., Wellcome Trust Case Control C., Holmans P.A., Owen M.J., O'Donovan M.C., Craddock N. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol. Psychiatry 2010, 15:1016-1022.
24. Grisaru N., Chudakov B., Yaroslavsky Y., Belmaker R.H. Transcranial magnetic stimulation in mania: a controlled study. Am. J. Psychiatry 1998, 155:1608-1610.
25. Harel E.V., Zangen A., Roth Y., Reti I., Braw Y., Levkovitz Y. H-coil repetitive transcranial magnetic stimulation for the treatment of bipolar depression: an add-on, safety and feasibility study. World J. Biol. Psychiatry 2011, 12:119-126.
26. Kaptsan A., Yaroslavsky Y., Applebaum J., Belmaker R.H., Grisaru N. Right prefrontal TMS versus sham treatment of mania: a controlled study. Bipolar Disord. 2003, 5:36-39.
27. Kessler R.C., Akiskal H.S., Ames M., Birnbaum H., Greenberg P., Hirschfeld R.M., Jin R., Merikangas K.R., Simon G.E., Wang P.S. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry 2006, 163:1561-1568.
28. Kulkarni J., Berk M., Wang W., Mu L., Scarr E., Van Rheenen T.E., Worsley R., Gurvich C., Gavrilidis E., de Castella A., Fitzgerald P., Davis S.R. A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology 2014, 43:52-61.
29. Kulkarni J., Garland K.A., Scaffidi A., Headey B., Anderson R., de Castella A., Fitzgerald P., Davis S.R. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006, 31:543-547.
30. Li X., Nahas Z., Anderson B., Kozel F.A., George M.S. Can left prefrontal rTMS be used as a maintenance treatment for bipolar depression?. Depress. Anxiety 2004, 20:98-100.
31. Magalhaes P.V., Dean O.M., Bush A.I., Copolov D.L., Malhi G.S., Kohlmann K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Berk M. A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Aust. N. Z. J. Psychiatry 2013, 47:564-568.
32. Maletic V., Raison C. Integrated neurobiology of bipolar disorder. Front. Psychiatry 2014, 5:98.
33. Merikangas K.R., Akiskal H.S., Angst J., Greenberg P.E., Hirschfeld R.M., Petukhova M., Kessler R.C. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch. Gen. Psychiatry 2007, 64:543-552.
34. Michael N., Erfurth A. Treatment of bipolar mania with right prefrontal rapid transcranial magnetic stimulation. J. Affect. Disord. 2004, 78:253-257.
35. Mitchell P.B., Hadzi-Pavlovic D. Lithium treatment for bipolar disorder. Bull. World Health Organ. 2000, 78:515-517.
36. Nahas Z., Kozel F.A., Li X., Anderson B., George M.S. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disord. 2003, 5:40-47.
37. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008, 11:851-876.
38. Ostacher M.J., Iosifescu D.V., Hay A., Blumenthal S.R., Sklar P., Perlis R.H. Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. Bipolar Disord. 2014, 16:199-203.
39. Parker G., McCraw S., Hadzi-Pavlovic D., Fletcher K. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J. Affect. Disord. 2013, 149:46-55.
40. Perlis R.H., Ostacher M.J., Patel J.K., Marangell L.B., Zhang H., Wisniewski S.R., Ketter T.A., Miklowitz D.J., Otto M.W., Gyulai L., Reilly-Harrington N.A., Nierenberg A.A., Sachs G.S., Thase M.E. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 2006, 163:217-224.
41. Perlis R.H., Smoller J.W., Ferreira M.A., McQuillin A., Bass N., Lawrence J., Sachs G.S., Nimgaonkar V., Scolnick E.M., Gurling H., Sklar P., Purcell S. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am. J. Psychiatry 2009, 166:718-725.
42. Phillips M.L., Swartz H.A. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am. J. Psychiatry 2014, 171:829-843.
43. Praharaj S.K., Ram D., Arora M. Efficacy of high frequency (rapid) suprathreshold repetitive transcranial magnetic stimulation of right prefrontal cortex in bipolar mania: a randomized sham controlled study. J. Affect. Disord. 2009, 117:146-150.
44. Rybakowski J.K. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs 2013, 27:165-173.
45. Saba G., Rocamora J.F., Kalalou K., Benadhira R., Plaze M., Lipski H., Januel D. Repetitive transcranial magnetic stimulation as an add-on therapy in the treatment of mania: a case series of eight patients. Psychiatry Res. 2004, 128:199-202.
46. Schoeyen H.K., Kessler U., Andreassen O.A., Auestad B.H., Bergsholm P., Malt U.F., Morken G., Oedegaard K.J., Vaaler A. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am. J. Psychiatry 2014.
47. Sklar P., Smoller J.W., Fan J., Ferreira M.A., Perlis R.H., Chambert K., Nimgaonkar V.L., McQueen M.B., Faraone S.V., Kirby A., de Bakker P.I., Ogdie M.N., Thase M.E., Sachs G.S., Todd-Brown K., Gabriel S.B., Sougnez C., Gates C., Blumenstiel B., Defelice M., Ardlie K.G., Franklin J., Muir W.J., McGhee K.A., MacIntyre D.J., McLean A., VanBeck M., McQuillin A., Bass N.J., Robinson M., Lawrence J., Anjorin A., Curtis D., Scolnick E.M., Daly M.J., Blackwood D.H., Gurling H.M., Purcell S.M. Whole-genome association study of bipolar disorder. Mol. Psychiatry 2008, 13:558-569.
48. Squassina A., Manchia M., Borg J., Congiu D., Costa M., Georgitsi M., Chillotti C., Ardau R., Mitropoulos K., Severino G., Del Zompo M., Patrinos G.P. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 2011, 12:1559-1569.
49. Strakowski S.M. The Bipolar Brain: Integrating Neuroimaging and Genetics 2012, Oxford, New York.
50. Tamas R.L., Menkes D., El-Mallakh R.S. Stimulating research: a prospective, randomized, double-blind, sham-controlled study of slow transcranial magnetic stimulation in depressed bipolar patients. J. Neuropsychiatry Clin. Neurosci. 2007, 19:198-199.
51. Tondo L., Baldessarini R.J., Vazquez G., Lepri B., Visioli C. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr. Scand. 2013, 127:355-364.
52. Wang S.M., Han C., Lee S.J., Patkar A.A., Masand P.S., Pae C.U. A review of current evidence for acetyl-l-carnitine in the treatment of depression. J. Psychiatr. Res. 2014, 53:30-37.
53. Yildiz A., Guleryuz S., Ankerst D.P., Ongur D., Renshaw P.F. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch. Gen. Psychiatry 2008, 65:255-263.
54. Zarate C., Machado-Vieira R., Henter I., Ibrahim L., Diazgranados N., Salvadore G. Glutamatergic modulators: the future of treating mood disorders?. Harv. Rev. Psychiatry 2010, 18:293-303.
55. Zarate C.A., Brutsche N.E., Ibrahim L., Franco-Chaves J., Diazgranados N., Cravchik A., Selter J., Marquardt C.A., Liberty V., Luckenbaugh D.A. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 2012, 71:939-946.
56. Zarate C.A., Quiroz J.A., Singh J.B., Denicoff K.D., De Jesus G., Luckenbaugh D.A., Charney D.S., Manji H.K. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry 2005, 57:430-432.
57. Zarate C.A., Singh J.B., Carlson P.J., Quiroz J., Jolkovsky L., Luckenbaugh D.A., Manji H.K. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007, 9:561-570.